D Orazio & Associates Inc. grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 20.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,983 shares of the medical research company’s stock after purchasing an additional 333 shares during the period. D Orazio & Associates Inc.’s holdings in Amgen were worth $493,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Morgan Stanley raised its holdings in shares of Amgen by 13.8% during the fourth quarter. Morgan Stanley now owns 9,745,556 shares of the medical research company’s stock worth $2,240,698,000 after acquiring an additional 1,179,665 shares in the last quarter. Norges Bank acquired a new stake in shares of Amgen in the fourth quarter valued at about $1,302,778,000. Aristotle Capital Management LLC lifted its stake in shares of Amgen by 5.5% in the fourth quarter. Aristotle Capital Management LLC now owns 4,395,783 shares of the medical research company’s stock valued at $1,006,606,000 after buying an additional 227,873 shares during the period. UBS Asset Management Americas Inc. lifted its stake in Amgen by 2.1% during the fourth quarter. UBS Asset Management Americas Inc. now owns 3,418,659 shares of the medical research company’s stock worth $786,018,000 after purchasing an additional 71,386 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Amgen by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,779,593 shares of the medical research company’s stock worth $639,084,000 after purchasing an additional 23,212 shares during the period. Institutional investors own 75.23% of the company’s stock.
In other news, Director Ronald D. Sugar sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 12th. The shares were sold at an average price of $250.59, for a total value of $250,590.00. Following the completion of the sale, the director now directly owns 16,927 shares in the company, valued at approximately $4,241,736.93. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 2,500 shares of the business’s stock in a transaction that occurred on Tuesday, May 11th. The stock was sold at an average price of $252.51, for a total transaction of $631,275.00. Following the completion of the sale, the senior vice president now owns 14,961 shares of the company’s stock, valued at $3,777,802.11. The disclosure for this sale can be found here. In the last three months, insiders sold 5,750 shares of company stock valued at $1,426,320. Corporate insiders own 0.36% of the company’s stock.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Monday, April 26th. The medical research company reported $3.70 EPS for the quarter, missing the Zacks’ consensus estimate of $4.05 by ($0.35). Amgen had a return on equity of 95.55% and a net margin of 29.42%. The company had revenue of $5.90 billion during the quarter, compared to analysts’ expectations of $6.30 billion. During the same period in the prior year, the firm earned $4.17 EPS. Amgen’s quarterly revenue was down 4.2% on a year-over-year basis. Analysts anticipate that Amgen Inc. will post 16.15 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 8th. Shareholders of record on Monday, May 17th will be paid a $1.76 dividend. The ex-dividend date of this dividend is Friday, May 14th. This represents a $7.04 dividend on an annualized basis and a yield of 2.78%. Amgen’s dividend payout ratio is presently 47.50%.
A number of research firms have commented on AMGN. The Goldman Sachs Group reaffirmed a “buy” rating and set a $290.00 target price on shares of Amgen in a report on Wednesday, April 28th. Royal Bank of Canada cut their price objective on shares of Amgen from $220.00 to $217.00 and set a “sector perform” rating on the stock in a research report on Tuesday, May 4th. Credit Suisse Group cut their price objective on shares of Amgen from $265.00 to $259.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 4th. Robert W. Baird reissued a “sell” rating on shares of Amgen in a research report on Thursday, April 29th. Finally, Piper Sandler lowered their price objective on shares of Amgen from $280.00 to $260.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 3rd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the stock. Amgen has a consensus rating of “Hold” and an average price target of $255.86.
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.